Efficacy and safety of pitavastatin in Japanese male children with familial hypercholesterolemia

Journal of Atherosclerosis and Thrombosis

Volumn 23, Issue 1, 2016, Pages 48-55

  Harada Shiba, Mariko ^a   Arisaka, Osamu ^b   Ohtake, Akira ^c   Okada, Tomoo ^d   Suganami, Hideki ^e   Shimura, Naoto ^b   Kikuchi, Toru ^c   Kodama, Hiroko ^f,n   Kaneko, Hideo ^g   Shimizu, Toshiaki ^h   Suzuki, Mitsuyoshi ^h   Niijima, Shinichi ⁱ   Uematsu, Ayumi ^j   Kishimoto, Ichiro ^a   Tamanaha, Tamiko ^a   Goji, Katsumi ^k   Yokota, Ichiro ^l   Nakamura, Kimitoshi ^m   Ogawa, Eishin ⁿ  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KOWA COMPANY LTD   (Japan)

^f TEIKYO HEISEI UNIVERSITY   (Japan)

^g NAGARA MEDICAL CENTER   (Japan)

^h JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

^j SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^k KOBE CHILDREN S HOSPITAL   (Japan)

^l SHIKOKU MEDICAL CENTER FOR CHILDREN AND ADULTS   (Japan)

^m KUMAMOTO UNIVERSITY   (Japan)

ⁿ TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Child; Efficacy; Familial hypercholesterolemia; Livalo ; Male; NK 104; Pitavastatin; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; TESTOSTERONE; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; QUINOLINE DERIVATIVE;

ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FOREARM FRACTURE; HUMAN; JAPANESE (PEOPLE); MALE; MULTICENTER STUDY; OBESITY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIALOADENITIS; TABLET; ADOLESCENT; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DYSLIPIDEMIAS; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE II; JAPAN; ORAL DRUG ADMINISTRATION; PATIENT SAFETY;

ADMINISTRATION, ORAL; ADOLESCENT; ANALYSIS OF VARIANCE; CHILD; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; JAPAN; MALE; PATIENT SAFETY; QUINOLINES;

EID: 85000869381     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.28753     Document Type: Article

References (14)

1. Harada-Shiba M, Arai H, Oikawa S, Ohta T, Okada T, Okamura T, Nohara A, Bujo H, Yokote K, Wakatsuki A, Ishibashi S, Yamashita S: Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb, 2012; 19: 1043-1060
2. Japan Atherosclerosis Society eds., Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012, Japan Atherosclerosis Society; 2012
3. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute: Expert Panel on Integrated Guidelines or Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics, 2011; 128 (Suppl 5): S213-256
4. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, Saito Y: Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittenforschung, 1997; 47: 904-909
5. Morikawa S, Umetani M, Nakagawa S, Yamazaki H, Suganami H, Inoue K, Kitahara M, Hamakubo T, Kodama T, Saito Y: Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler thromb, 2000; 7: 138-144
6. Suzuki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y: Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis, 1999; 146: 259-270
7. Nakaya N, Saito Y, Morisaki N, Tamura K, Shirai K, Shinomiya M, Kanzaki T, Hirose N, Tamachi H, Honma Y, Namiki M, Tochihara T, Koizumi K, Tada N: Phase II clinical study of NK-104 (pitavastatin) in patients with hyperlipidemia. J Clin Ther Med, 2001; 17: 789-806
8. Mabuchi H, Koizumi J, Kajinami K, Miyamoto S, Takegoshi T: Long-term effects of NK-104, a new HMG-CoA reductase inhibitor, in patients with heterozygous familial hypercholesterolemia. J Clin Ther Med, 2001; 17: 915-943
9. The Ministry of Education. Culture, Sports, Science and Technology: The Manual of Health Checkups of Students (revised edition). Japanese Society of School Health, 2006; 41-42
10. Knopp RH: Drug treatment of lipid disorders. N Engl J Med, 1999; 341: 498-511
11. Suzuki H, Ito H: Total testosterone, free testosterone. Nippon Rinsho, 1999; 57: 279-282. In Japanese
12. Toriumi M, Okazaki R, Tanaka K: Aldosterone. Nippon Rinsho, 1999; 57: 152-156. In Japanese
13. Kusters DM, Avis HJ, de Groot E, Wijburg FA, Kastelein JJ, Wiegman A, Hutten BA: Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia. JAMA, 2014; 312: 1055-1057
14. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S, Gylling H: Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev, 2010; 7: CD006401